These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 18024397

  • 1. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
    González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, Ribera JM, López A, Briones J, Muñoz A, Encuentra M, de Sevilla AF, GEL/TAMO (Grupo Español de Linfomas), GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear), GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas).
    Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
    [Abstract] [Full Text] [Related]

  • 2. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation.
    Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3945S-52S. PubMed ID: 14506193
    [Abstract] [Full Text] [Related]

  • 3. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dörken B, Oertel S.
    Transplantation; 2007 Apr 15; 83(7):912-8. PubMed ID: 17460562
    [Abstract] [Full Text] [Related]

  • 4. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, Hurault de Ligny B, Dubief F, Mathieu-Boue A, Leblond V.
    Ann Oncol; 2000 Apr 15; 11 Suppl 1():113-6. PubMed ID: 10707791
    [Abstract] [Full Text] [Related]

  • 5. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
    Knoop C, Kentos A, Remmelink M, Garbar C, Goldman S, Feremans W, Estenne M.
    Clin Transplant; 2006 Apr 15; 20(2):179-87. PubMed ID: 16640524
    [Abstract] [Full Text] [Related]

  • 6. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA.
    Cancer; 2005 Oct 15; 104(8):1661-7. PubMed ID: 16149091
    [Abstract] [Full Text] [Related]

  • 7. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
    Lee JJ, Lam MS, Rosenberg A.
    Ann Pharmacother; 2007 Oct 15; 41(10):1648-59. PubMed ID: 17848421
    [Abstract] [Full Text] [Related]

  • 8. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant.
    Dotti G, Rambaldi A, Fiocchi R, Motta T, Torre G, Viero P, Gridelli B, Barbui T.
    Haematologica; 2001 Jun 15; 86(6):618-23. PubMed ID: 11418370
    [Abstract] [Full Text] [Related]

  • 9. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC.
    J Clin Oncol; 2005 Sep 20; 23(27):6481-8. PubMed ID: 16170157
    [Abstract] [Full Text] [Related]

  • 10. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, German PTLD Study Group, European PTLD Network.
    Lancet Oncol; 2012 Feb 20; 13(2):196-206. PubMed ID: 22173060
    [Abstract] [Full Text] [Related]

  • 11. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J, Kotloff R, Tsai DE.
    Transpl Int; 2006 Apr 20; 19(4):259-69. PubMed ID: 16573540
    [Abstract] [Full Text] [Related]

  • 12. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
    Trappe RU, Choquet S, Reinke P, Dreyling M, Mergenthaler HG, Jäger U, Kebelmann-Betzing C, Jonas S, Lehmkuhl H, Anagnostopoulos I, Leblond V, Hetzer R, Dörken B, Riess H, Oertel S.
    Transplantation; 2007 Dec 27; 84(12):1708-12. PubMed ID: 18165786
    [Abstract] [Full Text] [Related]

  • 13. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.
    Fischer A, Blanche S, Le Bidois J, Bordigoni P, Garnier JL, Niaudet P, Morinet F, Le Deist F, Fischer AM, Griscelli C.
    N Engl J Med; 1991 May 23; 324(21):1451-6. PubMed ID: 2023604
    [Abstract] [Full Text] [Related]

  • 14. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.
    Choquet S, Oertel S, LeBlond V, Riess H, Varoqueaux N, Dörken B, Trappe R.
    Ann Hematol; 2007 Aug 23; 86(8):599-607. PubMed ID: 17522862
    [Abstract] [Full Text] [Related]

  • 15. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
    Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski JZ.
    Cancer; 2006 Oct 01; 107(7):1542-50. PubMed ID: 16948126
    [Abstract] [Full Text] [Related]

  • 16. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
    Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S.
    J Clin Oncol; 2017 Feb 10; 35(5):536-543. PubMed ID: 27992268
    [Abstract] [Full Text] [Related]

  • 17. Post-transplant lymphoproliferative disorders in children: the role of chemotherapy in the era of rituximab.
    Gallego S, Llort A, Gros L, Sanchez de Toledo J, Bueno J, Moreno A, Nieto J, Sanchez de Toledo J.
    Pediatr Transplant; 2010 Feb 10; 14(1):61-6. PubMed ID: 19344338
    [Abstract] [Full Text] [Related]

  • 18. Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
    Glez-Chamorro A, Jimenez C, Moreno-Glez E, Glez-Pinto I, Loinaz C, Gomez R, Garcia I, Alonso O, Palma F, Grande C.
    Hepatogastroenterology; 2000 Feb 10; 47(31):211-9. PubMed ID: 10690611
    [Abstract] [Full Text] [Related]

  • 19. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders.
    Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW.
    J Clin Oncol; 2005 Feb 20; 23(6):1096-102. PubMed ID: 15657402
    [Abstract] [Full Text] [Related]

  • 20. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
    Bosly A, Keating MJ, Stasi R, Bradstock K.
    Anticancer Drugs; 2002 Nov 20; 13 Suppl 2():S25-33. PubMed ID: 12710588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.